Literature DB >> 23860441

High population frequencies of APOL1 risk variants are associated with increased prevalence of non-diabetic chronic kidney disease in the Igbo people from south-eastern Nigeria.

Ifeoma I Ulasi1, Shay Tzur, Walter G Wasser, Revital Shemer, Etty Kruzel, Elena Feigin, Chinwuba K Ijoma, Obinna D Onodugo, Julius U Okoye, Ejikeme B Arodiwe, Ngozi A Ifebunandu, Chinwe J Chukwuka, Cajetan C Onyedum, Uchenna N Ijoma, Emmanuel Nna, Macaulay Onuigbo, Saharon Rosset, Karl Skorecki.   

Abstract

BACKGROUND: Continental Africa is facing an epidemic of chronic kidney disease (CKD). APOL1 risk variants have been shown to be strongly associated with an increased risk for non-diabetic kidney disease including HIV nephropathy, primary non-monogenic focal and segmental glomerulosclerosis, and hypertension-attributed nephropathy among African ancestry populations in the USA. The world's highest frequencies of APOL1 risk alleles have been reported in West African nations, overlapping regions with a high incidence of CKD and hypertension. One such region is south-eastern Nigeria, and therefore we sought to quantify the association of APOL1 risk alleles with CKD in this region.
METHODS: APOL1 risk variants were genotyped in a case-control sample set consisting of non-diabetic, CKD patients (n = 44) and control individuals (n = 43) from Enugu and Abakaliki, Nigeria.
RESULTS: We found a high frequency of two APOL1 risk alleles in the general population of Igbo people of south-eastern Nigeria (23.3%). The two APOL1 risk allele frequency in the CKD patient group was 66%. Logistic regression analysis under a recessive inheritance model showed a strong and significant association of APOL1 two-risk alleles with CKD, yielding an odds ratio of 6.4 (unadjusted p = 1.2E-4); following correction for age, gender, HIV and BMI, the odds ratio was 4.8 (adjusted p = 5.1E-03).
CONCLUSION: APOL1 risk variants are common in the Igbo population of south-eastern Nigeria, and are also highly associated with non-diabetic CKD in this area. APOL1 may explain the increased prevalence of CKD in this region.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23860441     DOI: 10.1159/000353223

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  43 in total

1.  ApoL1 Overexpression Drives Variant-Independent Cytotoxicity.

Authors:  John F O'Toole; William Schilling; Diana Kunze; Sethu M Madhavan; Martha Konieczkowski; Yaping Gu; Liping Luo; Zhenzhen Wu; Leslie A Bruggeman; John R Sedor
Journal:  J Am Soc Nephrol       Date:  2017-11-27       Impact factor: 10.121

Review 2.  Addressing the global burden of chronic kidney disease through clinical and translational research.

Authors:  Akinlolu Ojo
Journal:  Trans Am Clin Climatol Assoc       Date:  2014

3.  APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans.

Authors:  Alex N Kasembeli; Raquel Duarte; Michèle Ramsay; Pulane Mosiane; Caroline Dickens; Thérèse Dix-Peek; Sophie Limou; Efe Sezgin; George W Nelson; Agnes B Fogo; Stewart Goetsch; Jeffrey B Kopp; Cheryl A Winkler; Saraladevi Naicker
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

4.  APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.

Authors:  Opeyemi A Olabisi; Jia-Yue Zhang; Lynn VerPlank; Nathan Zahler; Salvatore DiBartolo; John F Heneghan; Johannes S Schlöndorff; Jung Hee Suh; Paul Yan; Seth L Alper; David J Friedman; Martin R Pollak
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-23       Impact factor: 11.205

Review 5.  Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy.

Authors:  Barry I Freedman; Karl Skorecki
Journal:  Clin J Am Soc Nephrol       Date:  2014-06-05       Impact factor: 8.237

6.  Translational Genomics in Low- and Middle-Income Countries: Opportunities and Challenges.

Authors:  Fasil Tekola-Ayele; Charles N Rotimi
Journal:  Public Health Genomics       Date:  2015-06-26       Impact factor: 2.000

7.  Plasma apolipoprotein L1 levels do not correlate with CKD.

Authors:  Leslie A Bruggeman; John F O'Toole; Michael D Ross; Sethu M Madhavan; Marlene Smurzynski; Kunling Wu; Ronald J Bosch; Samir Gupta; Martin R Pollak; John R Sedor; Robert C Kalayjian
Journal:  J Am Soc Nephrol       Date:  2013-11-14       Impact factor: 10.121

Review 8.  APOL1 Kidney Disease Risk Variants: An Evolving Landscape.

Authors:  Patrick D Dummer; Sophie Limou; Avi Z Rosenberg; Jurgen Heymann; George Nelson; Cheryl A Winkler; Jeffrey B Kopp
Journal:  Semin Nephrol       Date:  2015-05       Impact factor: 5.299

Review 9.  Apolipoprotein L1 and Kidney Disease in African Americans.

Authors:  David J Friedman; Martin R Pollak
Journal:  Trends Endocrinol Metab       Date:  2016-03-03       Impact factor: 12.015

Review 10.  APOL1 kidney risk alleles: population genetics and disease associations.

Authors:  Sophie Limou; George W Nelson; Jeffrey B Kopp; Cheryl A Winkler
Journal:  Adv Chronic Kidney Dis       Date:  2014-09       Impact factor: 3.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.